<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337490</url>
  </required_header>
  <id_info>
    <org_study_id>MAP-7189</org_study_id>
    <nct_id>NCT03337490</nct_id>
  </id_info>
  <brief_title>A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice</brief_title>
  <official_title>A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayne Pharma International Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bioRASI, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayne Pharma International Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group&#xD;
      design study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is comprised of two phases: screening and treatment. The screening period is 24&#xD;
      hours, followed by the treatment phase of 15 ± 3 days. During the treatment phase, subjects&#xD;
      will be randomized to either test, reference of placebo treatments (3:3:1) in a double-blind&#xD;
      manner in an outpatient setting. Once eligibility is confirmed, randomization will occur at&#xD;
      visit 2 (baseline, Day 1) i.e. initiation of treatment phase. The treatment phase will be 15&#xD;
      ± 3 days in duration wherein subject will receive treatment with investigational product&#xD;
      (either test, reference or placebo) on Day 1 or baseline (visit 2). Efficacy will be&#xD;
      evaluated at Day 15. Safety and tolerability will be evaluated based upon AEs and patient&#xD;
      self-assessments and self-assessments collected during follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Actual">December 18, 2017</completion_date>
  <primary_completion_date type="Actual">December 4, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Index Subjects Who Are Lice Free at Day 15</measure>
    <time_frame>15 Days</time_frame>
    <description>The primary endpoint is the proportion of index subjects who are lice free at Day 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of All Index Subjects Who Are Lice-free at Day 2</measure>
    <time_frame>2 Days</time_frame>
    <description>The secondary endpoint includes the number of all index subjects who are lice-free at Day 2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">296</enrollment>
  <condition>Head Lice</condition>
  <arm_group>
    <arm_group_label>Ivermectin 0.5% Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin 0.5% lotion, topical, 117g, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin 0.5% Lotion [SKLICE]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sklice 0.5% Lotion, topical, 117g, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0% Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0% lotion, 117g, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 0.5% Topical Application Lotion</intervention_name>
    <description>Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
    <arm_group_label>Ivermectin 0.5% Lotion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 0.5% Topical Application Lotion [SKLICE]</intervention_name>
    <description>Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
    <arm_group_label>Ivermectin 0.5% Lotion [SKLICE]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0% Lotion</intervention_name>
    <description>Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.</description>
    <arm_group_label>Placebo 0% Lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have an active head lice infestation defined as: At least 3 live lice&#xD;
             (adults and/or nymphs) present on the scalp and/or hair, as determined by a trained&#xD;
             evaluator. The index subject must be the youngest family member, through the age of&#xD;
             18, presenting with an active head lice infestation.&#xD;
&#xD;
          2. Household members that have an active head lice infestation defined as: At least 1&#xD;
             live louse (adult and/or nymph) present on the scalp and/or hair, as determined by a&#xD;
             trained evaluator (with the exception of the male head of household who may&#xD;
             self-assess as being lice free) will receive the Standard of Care with an&#xD;
             over-the-counter head lice treatment product. Up to 3 infested household members may&#xD;
             receive treatment, if more than 3 household members are infested, the entire household&#xD;
             will be excluded from the study.&#xD;
&#xD;
          3. Subject is male or female.&#xD;
&#xD;
          4. Index subject is at least 6 months through 18 years of age at time of enrollment.&#xD;
&#xD;
          5. Subject is in good general health based on medical history.&#xD;
&#xD;
          6. Each subject must have an appropriately signed Informed Consent agreement. A caregiver&#xD;
             must sign an Informed Consent agreement for children not old enough to do so. Children&#xD;
             ages 6-17 years of age will be administered a child's Assent Form.&#xD;
&#xD;
          7. The caregiver of a subject must be willing to allow all household members to be&#xD;
             screened for head lice. If other household members are found to have an active head&#xD;
             lice infestation, they must be willing and able to participate in receiving the&#xD;
             Standard of Care. No more than one working male per household may be excluded from&#xD;
             evaluation if he is assessed as being lice free by himself or the caregiver and cannot&#xD;
             come in due to his work schedule. If this individual may have lice, he must come to&#xD;
             the test facility; otherwise the entire household will be excluded from study&#xD;
             participation.&#xD;
&#xD;
          8. Subject and/or their caregiver must be physically able and willing to apply the test&#xD;
             product according to established treatment methods.&#xD;
&#xD;
          9. Subject agrees not to use any other form of lice treatments (commercial,&#xD;
             community-anecdotal, or mechanical/manual) while participating in the study.&#xD;
&#xD;
         10. Following application and rinsing of the test product, subject agrees not to shampoo,&#xD;
             wash, or rinse their hair or scalp until the 24-hour post-treatment evaluation has&#xD;
             been completed.&#xD;
&#xD;
         11. Subject agrees to not cut or chemically treat their hair while participating in the&#xD;
             study.&#xD;
&#xD;
         12. Subject agrees to follow all study instructions, including attending all follow-up&#xD;
             appointments.&#xD;
&#xD;
         13. Female index subjects of childbearing potential must be willing to have a urine&#xD;
             pregnancy test prior to inclusion in this study.&#xD;
&#xD;
         14. In the event of a subject judged to be incapable of self-treating, the household must&#xD;
             have a caregiver willing to apply the treatment at home.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Index subjects with greater than 3 household members with at least 1 live louse (adult&#xD;
             and/or nymph) present on the scalp and/or hair, as determined by a trained evaluator&#xD;
             will be automatically excluded from the trial.&#xD;
&#xD;
          2. Youngest household member is over 18 years of age.&#xD;
&#xD;
          3. History of irritation or sensitivity to ivermectin or the lotion components,&#xD;
             pediculicides or hair care products.&#xD;
&#xD;
          4. Presentation at the treatment site with visible skin/scalp condition(s) that are not&#xD;
             attributable to head lice infestation, such as an erythema score that is &gt;2, blisters,&#xD;
             vesicles which, in the opinion of the investigative personnel or medical monitor, will&#xD;
             interfere with safety and/or efficacy evaluations.&#xD;
&#xD;
          5. Presentation at the treatment site with eczema or atopic dermatitis.&#xD;
&#xD;
          6. Treatment for head lice (Over the counter [OTC], home remedy and/or Prescription) in&#xD;
             the last 15 days.&#xD;
&#xD;
          7. Any condition or illness that, in the opinion of the investigator, may compromise the&#xD;
             objective of the protocol.&#xD;
&#xD;
          8. Is receiving any other treatment which, in the opinion of the investigator or medical&#xD;
             monitor, may interfere with the study results.&#xD;
&#xD;
          9. Females (including caregivers who come in contact with the investigational product)&#xD;
             who are pregnant, nursing or planning a pregnancy which could include index subjects.&#xD;
             If a household has a pregnant female who has an active case of lice, the entire&#xD;
             household is excluded from participation. If this pregnant household member does not&#xD;
             have an active infestation, this individual must NOT be the caregiver (one who&#xD;
             provides treatment to other household members).&#xD;
&#xD;
         10. Index subject of child-bearing potential, and unwilling to use an adequate method of&#xD;
             contraception for the duration of the study. Adequate methods of contraception&#xD;
             include: abstinence, vasectomized partner, oral birth control pills, birth control&#xD;
             injections or patches, Intra uterine devices, condoms with a spermicidal jelly or a&#xD;
             diaphragm with spermicidal jelly, surgical sterilization. Index subjects and/or their&#xD;
             caregivers will be considered non-child-bearing if the following has occurred: full&#xD;
             hysterectomy or bilateral oophorectomy is considered surgically sterile. Tubal&#xD;
             ligation is not considered equivalent to female sterilization.&#xD;
&#xD;
         11. Participation in a previous investigational drug study within the past 30 days.&#xD;
&#xD;
         12. Does not understand the requirements for study participation and/or may likely exhibit&#xD;
             poor compliance, in the opinion of the investigator.&#xD;
&#xD;
         13. Does not have a known household affiliation with their household members (i.e., do not&#xD;
             stay in one household consistently, sleeping at one place several nights and then at&#xD;
             another place or location). Household is defined as living in a shared area or space&#xD;
             (for example the same house or apartment unit).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03337490/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03337490/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ivermectin 0.5% Lotion</title>
          <description>Ivermectin 0.5% lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion: Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
        <group group_id="P2">
          <title>Ivermectin 0.5% Lotion [SKLICE]</title>
          <description>Sklice 0.5% Lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion [SKLICE]: Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
        <group group_id="P3">
          <title>Placebo 0% Lotion</title>
          <description>0% lotion, 117g, single dose&#xD;
Placebo 0% Lotion: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 subject in the Ivermectin 0.5% Lotion [SKLICE] arm was not part of the mITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Ivermectin 0.5% Lotion</title>
          <description>Ivermectin 0.5% lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion: Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
        <group group_id="B2">
          <title>Ivermectin 0.5% Lotion [SKLICE]</title>
          <description>Sklice 0.5% Lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion [SKLICE]: Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
        <group group_id="B3">
          <title>Placebo 0% Lotion</title>
          <description>0% lotion, 117g, single dose&#xD;
Placebo 0% Lotion: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1 Month-2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-12 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-16 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;16 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Head Lice Visual Assessment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Index Subjects Who Are Lice Free at Day 15</title>
        <description>The primary endpoint is the proportion of index subjects who are lice free at Day 15</description>
        <time_frame>15 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin 0.5% Lotion</title>
            <description>Ivermectin 0.5% lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion: Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin 0.5% Lotion [SKLICE]</title>
            <description>Sklice 0.5% Lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion [SKLICE]: Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 0% Lotion</title>
            <description>0% lotion, 117g, single dose&#xD;
Placebo 0% Lotion: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Index Subjects Who Are Lice Free at Day 15</title>
          <description>The primary endpoint is the proportion of index subjects who are lice free at Day 15</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of All Index Subjects Who Are Lice-free at Day 2</title>
        <description>The secondary endpoint includes the number of all index subjects who are lice-free at Day 2</description>
        <time_frame>2 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin 0.5% Lotion</title>
            <description>Ivermectin 0.5% lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion: Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin 0.5% Lotion [SKLICE]</title>
            <description>Sklice 0.5% Lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion [SKLICE]: Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 0% Lotion</title>
            <description>0% lotion, 117g, single dose&#xD;
Placebo 0% Lotion: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of All Index Subjects Who Are Lice-free at Day 2</title>
          <description>The secondary endpoint includes the number of all index subjects who are lice-free at Day 2</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2.5 months from first subject first visit.</time_frame>
      <desc>No deaths or serious adverse events occurred during the duration of this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ivermectin 0.5% Lotion</title>
          <description>Ivermectin 0.5% lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion: Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
        <group group_id="E2">
          <title>Ivermectin 0.5% Lotion [SKLICE]</title>
          <description>Sklice 0.5% Lotion, topical, 117g, single dose&#xD;
Ivermectin 0.5% Topical Application Lotion [SKLICE]: Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
        <group group_id="E3">
          <title>Placebo 0% Lotion</title>
          <description>0% lotion, 117g, single dose&#xD;
Placebo 0% Lotion: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Upper Resporitory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Operations</name_or_title>
      <organization>Mayne Pharma LLC</organization>
      <phone>9195737948</phone>
      <email>phoevos.hughes@maynepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

